NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 149)
Posted On: 10/04/2023 5:23:44 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference
Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston.
The Acclaim-1 Phase 1 study results have demonstrated the safety and efficacy of REQORSA(R) in combination with Tagrisso(R), bringing hope to patients with late-stage NSCLC. Moreover, preclinical studies have highlighted REQORSA(R)’s potential in combination with a checkpoint inhibitor to combat chemotherapy-resistant small cell lung cancer (“SCLC”).
Two simultaneous presentations will showcase the company’s advancements on October 12 from 12:30 pm – 4:00 pm ET. Alexander I. Spira, M.D., PhD, Virginia Cancer Specialists, Fairfax, VA will be presenting “Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib.”
Concurrently, Ismail Meraz, Ph.D., Senior Research Project Manager, The University of Texas MD Anderson Cancer Center will be presenting “TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston.
The Acclaim-1 Phase 1 study results have demonstrated the safety and efficacy of REQORSA(R) in combination with Tagrisso(R), bringing hope to patients with late-stage NSCLC. Moreover, preclinical studies have highlighted REQORSA(R)’s potential in combination with a checkpoint inhibitor to combat chemotherapy-resistant small cell lung cancer (“SCLC”).
Two simultaneous presentations will showcase the company’s advancements on October 12 from 12:30 pm – 4:00 pm ET. Alexander I. Spira, M.D., PhD, Virginia Cancer Specialists, Fairfax, VA will be presenting “Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib.”
Concurrently, Ismail Meraz, Ph.D., Senior Research Project Manager, The University of Texas MD Anderson Cancer Center will be presenting “TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼